TRT Side Effects Overview: What Every Man Should Know Before Starting Testosterone Therapy

Erythrocytosis and Elevated Hematocrit: The Most Common TRT Side Effect

Erythrocytosis is the single most frequent laboratory abnormality during testosterone therapy. It happens because testosterone stimulates erythropoietin production in the kidneys, driving red blood cell mass upward. The Endocrine Society 2018 clinical practice guideline defines a hematocrit above 54% as the threshold for intervention, including dose reduction or temporary cessation [1].

Injection formulations produce the highest rates. A retrospective cohort analysis published in the Journal of Clinical Endocrinology & Metabolism found that 18.5% of men on intramuscular testosterone cypionate developed hematocrit values exceeding 54% within the first year, compared to 6.2% on transdermal gel [2]. The mechanism relates to the supraphysiologic peaks that follow each injection. Shorter dosing intervals (twice weekly rather than biweekly) flatten these peaks and reduce erythrocytosis risk.

The clinical concern is viscosity. Elevated hematocrit thickens blood, which raises the theoretical risk of venous thromboembolism, stroke, and myocardial infarction. A 2019 meta-analysis in Thrombosis Research found a modest but statistically significant association between TRT-induced polycythemia and venous thromboembolic events (OR 1.39 to 95% CI 1.05, 1.85) [3]. Monitoring is straightforward: a complete blood count at baseline, 3 months, 6 months, and every 6 to 12 months thereafter catches rising hematocrit before it reaches dangerous levels. Therapeutic phlebotomy remains the fastest correction when dose adjustment alone is insufficient.

Cardiovascular Risk: What the TRAVERSE Trial Actually Showed

For years, TRT's cardiac safety profile was uncertain. Two observational studies in 2013 and 2014 suggested increased cardiovascular events, prompting an FDA label update requiring manufacturers to warn of possible heart attack and stroke risk [4]. Those studies had significant methodological limitations, including confounding by indication and short follow-up windows.

The TRAVERSE trial settled the question with randomized evidence. Published in the New England Journal of Medicine in 2023, TRAVERSE enrolled 5,246 men aged 45, 80 with hypogonadism and preexisting or high risk of cardiovascular disease [5]. At a median follow-up of 33 months, the primary composite endpoint of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96 to 95% CI 0.78, 1.17). That result was noninferiority at the prespecified margin.

Dr. Shalender Bhasin, the trial's lead investigator, stated: "These findings should provide reassurance to clinicians and patients that testosterone replacement therapy in men with hypogonadism does not increase the short- to medium-term risk of major adverse cardiovascular events" [5].

One caveat: TRAVERSE did find a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm. These secondary endpoints did not meet statistical significance after multiplicity adjustment, but they warrant continued surveillance in men with preexisting arrhythmia risk factors [5].

Prostate Safety: Cancer Risk, BPH, and PSA Monitoring

The fear that testosterone causes prostate cancer originates from Charles Huggins' 1941 observation that castration shrank metastatic prostate tumors [6]. For decades, clinicians extrapolated (incorrectly) that adding testosterone would fuel new cancers. Modern evidence does not support that extrapolation.

A 2016 meta-analysis in European Urology pooled 22 randomized controlled trials involving 2,351 men treated with testosterone for 6 to 36 months and found no statistically significant difference in prostate cancer incidence compared to placebo (RR 0.87 to 95% CI 0.30, 2.50) [7]. The saturation model, proposed by Abraham Morgentaler at Harvard, provides the mechanistic explanation: androgen receptors in prostate tissue become fully saturated at relatively low serum testosterone levels (approximately 250 ng/dL), meaning that raising testosterone above this point does not produce additional receptor-mediated growth signaling [8].

Benign prostatic hyperplasia (BPH) deserves separate consideration. TRT may cause a modest 0.5, 1.0 point increase in International Prostate Symptom Score (IPSS) over the first 6 to 12 months [7]. Men with severe baseline lower urinary tract symptoms (IPSS above 19) should have urological evaluation before starting therapy. PSA typically rises 0.3 to 0.5 ng/mL in the first 6 months and then plateaus. The Endocrine Society recommends checking PSA at baseline, 3 to 6 months, 12 months, and annually thereafter, with urology referral triggered by a PSA rise exceeding 1.4 ng/mL over any 12-month period or an absolute value above 4.0 ng/mL [1].

Fertility Suppression and Testicular Atrophy

Exogenous testosterone shuts down the hypothalamic-pituitary-gonadal (HPG) axis. This is not a side effect that might happen. It will happen. Within 2 to 3 months of starting TRT, gonadotropin (LH and FSH) levels drop to near-zero, and intratesticular testosterone (required for spermatogenesis) falls by 90% or more [9].

Azoospermia develops in roughly 40% of men within 6 months, and severe oligospermia in most of the remainder [9]. Testicular volume decreases by approximately 20 to 25% due to seminiferous tubule atrophy. The suppression is dose-dependent but occurs even at replacement doses.

Recovery after discontinuation is possible but not guaranteed. A study in Fertility and Sterility followed 66 men after TRT cessation and found that 67% recovered to a sperm concentration of at least 20 million/mL within 12 months, but 10% remained severely oligospermic at 24 months [10]. Men who want to preserve fertility have options. Human chorionic gonadotropin (hCG) at 500, 1 to 000 IU two to three times weekly can maintain intratesticular testosterone and preserve spermatogenesis during TRT. Clomiphene citrate (off-label, 25 to 50 mg every other day) is another approach for men with borderline-low testosterone who want to avoid the fertility trade-off entirely [1].

Estrogen-Related Side Effects: Gynecomastia and Water Retention

Testosterone is a substrate for aromatase, the enzyme that converts androgens to estradiol. Higher testosterone doses and greater body fat percentage both increase aromatization. When estradiol rises disproportionately, men may develop gynecomastia (breast tissue growth), nipple tenderness, water retention, and mood lability.

The TRAVERSE trial reported gynecomastia in 2.2% of testosterone-treated men vs. 0.4% on placebo [5]. In clinical practice, estimates run higher (10 to 15%) because real-world populations include more obese men with elevated aromatase activity than trial cohorts typically do.

Monitoring estradiol levels at each lab draw is the first defense. The Endocrine Society does not recommend routine aromatase inhibitor (AI) use, but a sensitive estradiol level above 50 pg/mL combined with symptoms may warrant short-term anastrozole (0.5 mg twice weekly) or, more sustainably, a dose reduction and shift to more frequent injection intervals [1]. Weight loss itself lowers aromatase expression and can resolve estrogen-related symptoms without pharmacologic intervention.

Skin and Hair Effects

Acne is the most visible TRT side effect and affects 15 to 25% of men, usually in the first 3 to 6 months. It results from androgen-stimulated sebum production and tends to concentrate on the back, shoulders, and face. Mild cases respond to benzoyl peroxide or topical retinoids; moderate-to-severe cases may require oral doxycycline [11].

Androgenetic alopecia (male-pattern hair loss) may accelerate in men who are genetically predisposed. Testosterone itself is not the primary driver. Dihydrotestosterone (DHT), produced via 5-alpha reductase conversion, is the mediator. Finasteride (1 mg daily) or dutasteride (0.5 mg daily) can block this conversion, though their use alongside TRT requires discussion about potential sexual side effects of 5-alpha reductase inhibitors themselves [11].

Body hair growth, on the other hand, is androgen-dependent and commonly increases on TRT. Oily skin without frank acne is another frequent complaint that resolves with dose optimization.

Sleep Apnea and TRT

The Endocrine Society lists untreated severe obstructive sleep apnea (OSA) as a relative contraindication to TRT [1]. Testosterone may worsen OSA through several mechanisms: increased upper airway collapsibility, central adipose redistribution, and altered ventilatory drive during sleep. A 2014 randomized trial published in the Journal of Clinical Endocrinology & Metabolism found that testosterone administration in obese men with OSA increased the oxygen desaturation index by 10.3 events/hour compared to placebo (P=0.03) [12].

Not all men are affected equally. The risk concentrates in men who are already obese (BMI >35), have moderate-to-severe baseline OSA, or use supraphysiologic testosterone doses. Men starting TRT who snore heavily or have daytime hypersomnolence should undergo a baseline sleep study. Those already on CPAP can generally continue TRT safely with appropriate monitoring and CPAP compliance.

Mood, Behavior, and Psychological Effects

The "roid rage" stereotype comes from anabolic steroid abuse at supraphysiologic doses (often 5, 10 times replacement levels). At therapeutic replacement doses targeting mid-normal serum testosterone (500 to 700 ng/dL), randomized data consistently show mood improvements rather than aggression [13].

The TRAVERSE trial found no difference in rates of psychiatric adverse events between testosterone and placebo groups [5]. A 2019 systematic review in Psychoneuroendocrinology analyzed 27 RCTs and concluded that TRT at replacement doses improved depressive symptoms (standardized mean difference -0.23 to 95% CI -0.33 to -0.13) with no increase in anger, hostility, or aggression measures [13].

Where mood problems arise, they almost always trace to hormone fluctuations rather than absolute levels. The peak-trough cycle of biweekly injections can produce irritability at the peak and fatigue or low mood at the trough. Switching to twice-weekly subcutaneous injections or daily transdermal application smooths these fluctuations and typically resolves mood-related complaints within 4 to 6 weeks.

Monitoring Protocol: The Safety Net That Makes TRT Low-Risk

Every side effect discussed above is detectable before it becomes dangerous. The Endocrine Society 2018 guideline lays out a straightforward monitoring schedule [1]:

• Baseline: total testosterone (two morning draws), free testosterone, CBC, metabolic panel, lipid panel, PSA, estradiol, LH, FSH, DEXA if indicated
• 3 months: total testosterone (timed to trough for injections), CBC (hematocrit), PSA, estradiol, liver function
• 6 months: repeat the 3-month panel
• 12 months: full panel including lipids, repeat annually thereafter
• Ongoing: hematocrit every 6 months for the first 2 years, then annually; PSA annually; symptom questionnaire at each visit

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has noted: "The risk of TRT is not the testosterone itself. The risk is unmonitored testosterone. When you follow the evidence-based monitoring protocol, the safety profile of TRT is comparable to many commonly prescribed chronic medications" [1].

Men who follow this schedule and work with a knowledgeable prescriber can expect early detection and prompt correction of any laboratory or clinical abnormality. Hematocrit trending upward gets caught at month 3, not month 12. PSA velocity gets tracked before it reaches referral thresholds. Estradiol gets checked before gynecomastia becomes fibrotic and irreversible.

A 2-minute blood draw every few months is a small price for a therapy that, when properly managed, resolves the fatigue, sexual dysfunction, and metabolic deterioration of clinical hypogonadism.